Skip to content

Autologous bone marrow stem cells (BMSC) in patients with end stage liver diseases

Autologous bone marrow stem cells (BMSC) in patients with end stage liver diseases

Status
Active, not recruiting
Phases
Phase 2
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-12002103
Enrollment
Unknown
Registered
2012-04-11
Start date
2012-02-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end stage of liver diseases

Interventions

stem cells therapy:BMSC therapy

Sponsors

The 105st Hospital of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Aged 18-69 years, CHB,CHC,AFLD cirrhosis; ultrasonographic or CT evidences of cirrhosis and portal hypertension, mild ascitis,abnormal serum albumin20s, hematoglobin>=7.0 g/L, platelet >=300000/mL, a Child-Turcotte-Pugh score or prior CTP score >=7 at screen.

Exclusion criteria

Exclusion criteria: Severe hepatic encephalopathy or variceal bleeding; serum creatinine >=2 mg/dL, serum sodium<125 mEq/L; serum total bilirubin more than 3 mg/dL; presence of active untreated infectious disease; presence of hepatic, portal, or splenic vein thromboses on Doppler ultrasonography; presence of severe comorbid diseases (e.g., severe renal, respiratory, or cardiac disease), or presence of any type of malignancy; history of alcohol abuse, or use of hepatotoxic drugs within the last six months before enrolment; active substance abuse; pregnancy or lactation; can not sign the informed consent.

Design outcomes

Primary

MeasureTime frame
Death;TBil ALT AST;ALB, CHO, CHE, AT;

Contacts

Public Contactcongxin chen
congxinc@yahoo.com.cn+86 18909696271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026